Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

BAI1 as a Prognostic Marker of Clear Cell Renal Cell Carcinoma (ccRCC)

M. Pesta, I. Travnicek, V. Kulda, J. Windrichova, H. Rezackova, K. Houfkova, T. Macanova, B. Bendova, A. Nestorova, O. Hes, M. Hora, O. Topolcan, J. Polivka

. 2021 ; 41 (9) : 4463-4470. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024987

BACKGROUND/AIM: The treatment of advanced clear cell renal cell carcinoma (ccRCC) is based on stratification of patients according to prognosis (favorable, intermediate, and poor). The aim of the study was to improve prognostication by biomarkers involved in angiogenesis. PATIENTS AND METHODS: The study group consisted of 20 patients who underwent surgery for ccRCC. Gene expression analysis was peformed on a set of matched (primary tumor, metastasis, n=20+20) FFPE tissue samples. An additional analysis was done on expression data of 606 patients obtained from the TCGA Kidney Clear Cell Carcinoma (KIRC) database. Quantitative estimation of mRNA of selected genes (TaqMan human Angiogenesis Array, 97 genes) was performed by a real-time RT-PCR method with TaqMan® arrays. RESULTS: Using the Cox regression model, 4 genes (PDGFB, FGF4, EPHB2 and BAI1) were identified whose expression was related to progression-free interval (PFI). Further analysis using the Kaplan Meier method conclusively revealed the relationship of BAI1 expression to prognosis (both datasets). Patients with higher BAI1 expression had significantly shorter PFI and overall survival. CONCLUSION: We showed that tumor tissue BAI1 expression level is a prognostic marker in ccRCC. Therefore, this gene might be involved in a prognostic panel to improve scoring systems on which the management of metastatic ccRCC patients is based.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024987
003      
CZ-PrNML
005      
20211026134229.0
007      
ta
008      
211013s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.15255 $2 doi
035    __
$a (PubMed)34475070
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Pesta, Martin $u Department of Biology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic
245    10
$a BAI1 as a Prognostic Marker of Clear Cell Renal Cell Carcinoma (ccRCC) / $c M. Pesta, I. Travnicek, V. Kulda, J. Windrichova, H. Rezackova, K. Houfkova, T. Macanova, B. Bendova, A. Nestorova, O. Hes, M. Hora, O. Topolcan, J. Polivka
520    9_
$a BACKGROUND/AIM: The treatment of advanced clear cell renal cell carcinoma (ccRCC) is based on stratification of patients according to prognosis (favorable, intermediate, and poor). The aim of the study was to improve prognostication by biomarkers involved in angiogenesis. PATIENTS AND METHODS: The study group consisted of 20 patients who underwent surgery for ccRCC. Gene expression analysis was peformed on a set of matched (primary tumor, metastasis, n=20+20) FFPE tissue samples. An additional analysis was done on expression data of 606 patients obtained from the TCGA Kidney Clear Cell Carcinoma (KIRC) database. Quantitative estimation of mRNA of selected genes (TaqMan human Angiogenesis Array, 97 genes) was performed by a real-time RT-PCR method with TaqMan® arrays. RESULTS: Using the Cox regression model, 4 genes (PDGFB, FGF4, EPHB2 and BAI1) were identified whose expression was related to progression-free interval (PFI). Further analysis using the Kaplan Meier method conclusively revealed the relationship of BAI1 expression to prognosis (both datasets). Patients with higher BAI1 expression had significantly shorter PFI and overall survival. CONCLUSION: We showed that tumor tissue BAI1 expression level is a prognostic marker in ccRCC. Therefore, this gene might be involved in a prognostic panel to improve scoring systems on which the management of metastatic ccRCC patients is based.
650    _2
$a angiogenní proteiny $x genetika $7 D042501
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a karcinom z renálních buněk $x genetika $x mortalita $x chirurgie $7 D002292
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $x metody $7 D020869
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a nádory ledvin $x genetika $x mortalita $x chirurgie $7 D007680
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a sekvenční analýza hybridizací s uspořádaným souborem oligonukleotidů $7 D020411
650    _2
$a prognóza $7 D011379
650    _2
$a receptory spřažené s G-proteiny $x genetika $7 D043562
650    _2
$a regresní analýza $7 D012044
650    _2
$a analýza přežití $7 D016019
650    12
$a upregulace $7 D015854
655    _2
$a časopisecké články $7 D016428
700    1_
$a Travnicek, Ivan $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Kulda, Vlastimil $u Department of Medical Chemistry and Biochemistry, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic; vlastimil.kulda@lfp.cuni.cz
700    1_
$a Windrichova, Jindra $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic $u Department of Medical Chemistry and Biochemistry, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Rezackova, Hana $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Houfkova, Katerina $u Department of Biology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Macanova, Tereza $u Department of Biology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Bendova, Barbora $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Nestorova, Andrea $u Department of Medical Chemistry and Biochemistry, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Hes, Ondrej $u Department of Pathology, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Hora, Milan $u Department of Urology, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Topolcan, Ondrej $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic
700    1_
$a Polivka, Jiri $u Laboratory of Immunoanalysis, University Hospital in Pilsen, Pilsen, Czech Republic $u Department of Histology and Embryology, Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 41, č. 9 (2021), s. 4463-4470
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34475070 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134235 $b ABA008
999    __
$a ok $b bmc $g 1714156 $s 1145494
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 41 $c 9 $d 4463-4470 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace